UK based Rosemont Pharmaceuticals appoints new chairperson with wealth of experience in the US pharma market

Irish born Sharon Curran, has been appointed as the new chairperson for Rosemont Pharmaceuticals board of directors.

The company manufactures and specialises in novel, Rx oral liquid medicines for patients who have difficulty swallowing due to conditions such as dysphagia, stroke or dementia.

Ms Curran has held extensive senior and executive leadership roles in healthcare including non-executive board positions at businesses across Europe and the United States, notably AbbVie in Chicago.

Her experience includes leading high impact global marketing, commercialisation and growth strategies for world class pharmaceutical corporations.

Her appointment is part of Rosemont’s expansion into the global and US market, following the acquisition of US based Sabal Therapeutics in 2024. The company already has partnerships across North America including Canada, Middle East and Asia.

Rosemont’s Interim Chief Executive, Tim Busby said: “All of us at Rosemont are looking forward to working with Sharon as she brings her global knowledge and experience to the business.

“We are confident her expertise will be invaluable as we continue our expansion globally and across the US and strive towards treating more patients who need liquid medicines to maintain their health.”

Rosemont was acquired by the private equity firm Inflexion in 2020 and has increasingly been looking to expand outside of the UK and into other markets since then.

 

ROS000238-001 DOP July 2025